Peter Cornelisse

3.8k total citations · 1 hit paper
46 papers, 3.0k citations indexed

About

Peter Cornelisse is a scholar working on Infectious Diseases, Epidemiology and Pathology and Forensic Medicine. According to data from OpenAlex, Peter Cornelisse has authored 46 papers receiving a total of 3.0k indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Infectious Diseases, 17 papers in Epidemiology and 10 papers in Pathology and Forensic Medicine. Recurrent topics in Peter Cornelisse's work include HIV/AIDS Research and Interventions (20 papers), HIV, Drug Use, Sexual Risk (15 papers) and HIV Research and Treatment (7 papers). Peter Cornelisse is often cited by papers focused on HIV/AIDS Research and Interventions (20 papers), HIV, Drug Use, Sexual Risk (15 papers) and HIV Research and Treatment (7 papers). Peter Cornelisse collaborates with scholars based in Canada, United States and Switzerland. Peter Cornelisse's co-authors include Steffanie A. Strathdee, Martin T. Schechter, Michael L. Rekart, David M. Patrick, Sue Currie, Julio Montaner, Michael V. O’Shaughnessy, M. V. O'Shaughnessy, Robert S. Hogg and Kevin J.P. Craib and has published in prestigious journals such as Journal of the American College of Cardiology, Neurology and American Journal of Epidemiology.

In The Last Decade

Peter Cornelisse

44 papers receiving 2.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Needle exchange is not enough

1997 519 citations Steffanie A. Strathdee, David M. Patrick et al. AIDS profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Peter Cornelisse Canada	26	1.6k	1.2k	604	566	539	46	3.0k
Wendy A. Leyden United States	26	1.5k 1.0×	1.1k 0.9×	237 0.4×	358 0.6×	142 0.3×	58	3.4k
Michaël Schwarzinger France	27	1.2k 0.8×	915 0.8×	171 0.3×	216 0.4×	190 0.4×	85	3.1k
Xiangrong Kong United States	33	631 0.4×	426 0.3×	178 0.3×	116 0.2×	501 0.9×	102	3.2k
Peter Holck United States	27	604 0.4×	324 0.3×	401 0.7×	60 0.1×	422 0.8×	60	2.9k
Mary Culnane United States	24	2.3k 1.4×	4.5k 3.7×	1.1k 1.7×	97 0.2×	633 1.2×	38	6.7k
Harry W. Haverkos United States	28	1.2k 0.8×	777 0.6×	210 0.3×	112 0.2×	216 0.4×	66	2.7k
William Towner United States	27	1.2k 0.7×	2.3k 1.9×	164 0.3×	218 0.4×	140 0.3×	80	3.6k
Sylvia Cohn United States	28	2.1k 1.3×	1.1k 0.9×	359 0.6×	100 0.2×	302 0.6×	46	2.9k
Miriam Chernoff United States	22	313 0.2×	641 0.5×	313 0.5×	264 0.5×	259 0.5×	37	2.9k
Peter J. Davidson United States	35	2.0k 1.2×	363 0.3×	386 0.6×	58 0.1×	1.9k 3.6×	121	3.8k

Countries citing papers authored by Peter Cornelisse

Since Specialization

Citations

This map shows the geographic impact of Peter Cornelisse's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Peter Cornelisse with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Peter Cornelisse more than expected).

Fields of papers citing papers by Peter Cornelisse

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Peter Cornelisse. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Peter Cornelisse. The network helps show where Peter Cornelisse may publish in the future.

Co-authorship network of co-authors of Peter Cornelisse

This figure shows the co-authorship network connecting the top 25 collaborators of Peter Cornelisse. A scholar is included among the top collaborators of Peter Cornelisse based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Peter Cornelisse. Peter Cornelisse is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Flack, John M., Krzysztof Narkiewicz, Martine Clozel, et al.. (2025). EFFECT OF APROCITENTAN ON BLOOD PRESSURE AND ALBUMINURIA IN PATIENTS WITH RESISTANT HYPERTENSION TREATED WITH SODIUM-GLUCOSE COTRANSPORTER-2 INHIBITORS (SGLT2I). Journal of the American College of Cardiology. 85(12). 461–461. 1 indexed citations

Héron, Bénédicte, Spyros Batzios, Eugen Mengel, et al.. (2024). A natural history study of pediatric patients with early onset of GM1 gangliosidosis, GM2 gangliosidoses, or gaucher disease type 2 (RETRIEVE). Orphanet Journal of Rare Diseases. 19(1). 459–459. 1 indexed citations

Askanase, Anca, David D’Cruz, Kenneth Kalunian, et al.. (2024). Cenerimod, a sphingosine-1-phosphate receptor modulator, versus placebo in patients with moderate-to-severe systemic lupus erythematosus (CARE): an international, double-blind, randomised, placebo-controlled, phase 2 trial. The Lancet Rheumatology. 7(1). e21–e32. 5 indexed citations

Askanase, Anca, David D’Cruz, Kenneth Kalunian, et al.. (2023). POS1147 EFFICACY OF CENERIMOD IN PATIENTS WITH HIGH IFN-1 GENE EXPRESSION SIGNATURE AND HIGH ANTI-DSDNA ANTIBODY LEVELS: POST-HOC ANALYSIS FROM A PHASE 2 STUDY. Annals of the Rheumatic Diseases. 82. 903–904.

Wanner, Christoph, Virginia Kimonis, Juan Politei, et al.. (2022). Understanding and modifying Fabry disease: Rationale and design of a pivotal Phase 3 study and results from a patient-reported outcome validation study. Molecular Genetics and Metabolism Reports. 31. 100862–100862. 15 indexed citations

Bauer, Yasmina, Simon de Bernard, Peter Hickey, et al.. (2020). Identifying early pulmonary arterial hypertension biomarkers in systemic sclerosis: machine learning on proteomics from the DETECT cohort. European Respiratory Journal. 57(6). 2002591–2002591. 60 indexed citations

Berger, Rolf M.F., Martine Géhin, Maurice Beghetti, et al.. (2017). A bosentan pharmacokinetic study to investigate dosing regimens in paediatric patients with pulmonary arterial hypertension: FUTURE‐3. British Journal of Clinical Pharmacology. 83(8). 1734–1744. 20 indexed citations

Patterson, Marc C., Eugen Mengel, Marie T. Vanier, et al.. (2015). Stable or improved neurological manifestations during miglustat therapy in patients from the international disease registry for Niemann-Pick disease type C: an observational cohort study. Orphanet Journal of Rare Diseases. 10(1). 65–65. 69 indexed citations

Kappos, Ludwig, Jens Kühle, Marcelo Kremenchutzky, et al.. (2015). Factors influencing long-term outcomes in relapsing–remitting multiple sclerosis: PRISMS-15. Journal of Neurology Neurosurgery & Psychiatry. 86(11). 1202–1207. 70 indexed citations

10.

Matucci‐Cerinic, Marco, Thomas Krieg, Loı̈c Guillevin, et al.. (2015). Elucidating the burden of recurrent and chronic digital ulcers in systemic sclerosis: long-term results from the DUO Registry. Annals of the Rheumatic Diseases. 75(10). 1770–1776. 65 indexed citations

11.

Sormani, Maria Pia, Jordi Río, Mar Tintoré, et al.. (2012). Scoring treatment response in patients with relapsing multiple sclerosis. Multiple Sclerosis Journal. 19(5). 605–612. 187 indexed citations

12.

Uitdehaag, Bernard M.J., Peter Cornelisse, Douglas Jeffery, et al.. (2010). Associations between annualized relapse rate and long-term exposure to subcutaneous interferon beta-1a in the Prevention of Relapses and disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis (PRISMS) long-term follow-up study. Journal of Neurology. 257. 456–456. 1 indexed citations

13.

Morrison, Charles, Barbra A. Richardson, Francis Mmiro, et al.. (2006). Hormonal contraception and the risk of HIV acquisition. AIDS. 21(1). 85–95. 155 indexed citations

14.

Cornelisse, Peter, Benita Yip, Kevin J.P. Craib, et al.. (2000). The impact of zidovudine on dementia-free survival in a population of HIV-positive men and women on antiretroviral therapy. International Journal of STD & AIDS. 11(1). 52–56. 4 indexed citations

15.

Craib, Kevin J.P., Peter Cornelisse, Mary Lou Miller, et al.. (2000). Comparison of sexual behaviors, unprotected sex, and substance use between two independent cohorts of gay and bisexual men. AIDS. 14(3). 303–311. 25 indexed citations

16.

Schechter, Martin T., Steffanie A. Strathdee, Peter Cornelisse, et al.. (1999). Do needle exchange programmes increase the spread of HIV among injection drug users?: an investigation of the Vancouver outbreak. AIDS. 13(6). F45–F51. 148 indexed citations

17.

Veugelers, Paul J., Peter Cornelisse, Kevin J.P. Craib, et al.. (1998). Models of Survival in HIV Infection and Their Use in the Quantification of Treatment Benefits. American Journal of Epidemiology. 148(5). 487–496. 20 indexed citations

18.

Strathdee, Steffanie A., Robert S. Hogg, Peter Cornelisse, et al.. (1998). Determinants of Sexual Risk-Taking Among Young HIV-Negative Gay and Bisexual Men. Journal of Acquired Immune Deficiency Syndromes & Human Retrovirology. 19(1). 61–66. 161 indexed citations

19.

Patrick, David M., Steffanie A. Strathdee, Marianna Ofner, et al.. (1997). Determinants of HIV seroconversion in drug users during a period of rising prevalence in Vancouver. International Journal of STD & AIDS. 8(7). 437–445. 107 indexed citations

20.

Cornelisse, Peter, Katherine Heath, Kevin J.P. Craib, et al.. (1997). Determinants of Complementary Therapy Use in HIV-Infected Individuals Receiving Antiretroviral or Anti-opportunistic Agents. Journal of Acquired Immune Deficiency Syndromes & Human Retrovirology. 15(2). 115–120. 43 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact